GB2612481A - A novel medicament for immune modulation and treating chronic or hyper inflammation - Google Patents

A novel medicament for immune modulation and treating chronic or hyper inflammation Download PDF

Info

Publication number
GB2612481A
GB2612481A GB2300774.3A GB202300774A GB2612481A GB 2612481 A GB2612481 A GB 2612481A GB 202300774 A GB202300774 A GB 202300774A GB 2612481 A GB2612481 A GB 2612481A
Authority
GB
United Kingdom
Prior art keywords
use according
medicament
treatment
anabasine
immune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB2300774.3A
Other versions
GB202300774D0 (en
Inventor
Fadly Abd El Ghany Elkazaz Mohamed
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of GB202300774D0 publication Critical patent/GB202300774D0/en
Publication of GB2612481A publication Critical patent/GB2612481A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Present invention is a designation of a novel medicament for immune modulation and treating chronic or hyper inflammation. Its active ingredient is anabasine or its salt. It was designed for example to treat some of auto immune diseases permanently such as asthma and atopic dermatitis by one medication course, to stop the progression and development of diabetes type 2 in diabetics and restoring their blood sugar to normal with respect to administration in the disease early stages, to prevent the incidence and development of autoimmune Diabetes Type 1 resulted from T cell-mediated damage of pancreatic β-cells and loss of insulin production. Further, it plays a pivotal and protective role in treating hazardous infections caused by diverse pathogens to promote and accelerate recovery, including COVID -19 with its variants.

Claims (1)

  1. Claims
    1- Use of anabasine in the preparation of a human medicament for immune modulation and treating chronic or hyper inflammation .
    2- Use of anabasine in the preparation of a human medicament for the innate immune modulation and treating chronic or hyper inflammation .
    3- The use according to either claim 1 or 2 is for the treatment of auto immune diseases and as an immune modulator medicament for these diseases .
    4- The use according to either claim 1 or 2 is for the treatment of all infections types as microbial infections , protozoan infections , prion disease and other infections including those caused by ectoparasites , as an immune modulator and pivotal / protective treatment .
    5- The use according to either claim 1 or 2 is for inhibiting or controlling hypercytokinemia induced by infectious or non-infectious etiologies as an immune modulator .
    6- The use according to either claim 1 or 2 is for the therapeutic treatment of diabetes type 2 , stopping the progression and development of diabetes type 2 in diabetics and restoring their blood sugar to normal with respect to the administration in disease first / early stages as an immune modulator .
    7- The use according to either claim lor 2 is a treatment for preventing the incidence and development of autoimmune Diabetes Type 1 , particularly which resulted from T cell- mediated damage of pancreatic b-cells and loss of insulin production as an immune modulator .
    8- The use according to either claim 1 or 2 is for the therapeutic treatment of asthma types, chest allergy and atopic dermatitis permanently .
    9- The use according to either claim 1 or 2 is for the therapeutic treatment of chronic systemic inflammation , systemic inflammation or systemic inflammation response syndrome particularly which due to internal (genetic mutations/variations) factors and as an immune modulator medicament .
    10- The use according to claim 1 or 2 or 3 or 4 or 5 or 9 wherein subject in need to such treatment is an animal .
    11- The pharmaceutical composition of the said medicament according to any preceding claim is comprising of anabasine as an active ingredient or its salt and a pharmacologically acceptable excipient , diluent or carrier.
    12- The pharmaceutical composition of the said medicament according to claims from 1 to 10 is comprising of anabasine as an active ingredient at concentration of anabasine from 0.01 mg /kg : 3.5 mg / kg of body weight or its salt and a pharmacologically acceptable excipient , diluent or carrier.
    13- The use according to any preceding claim wherein said medicament with said pharmaceutical composition is for systemic , local or topical administration .
    14- The use according to any preceding claim wherein said medicament with said pharmaceutical composition further comprises or may be co-administered with an existing therapeutic agent for achieving , treating or managing any said purposes , diseases or conditions in claims 1 to 9 .
GB2300774.3A 2020-06-09 2021-06-07 A novel medicament for immune modulation and treating chronic or hyper inflammation Pending GB2612481A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EG2020060768 2020-06-09
PCT/EG2021/000016 WO2021249608A2 (en) 2020-06-09 2021-06-07 A novel medicament for immune modulation and treating chronic or hyper inflammation

Publications (2)

Publication Number Publication Date
GB202300774D0 GB202300774D0 (en) 2023-03-08
GB2612481A true GB2612481A (en) 2023-05-03

Family

ID=78845336

Family Applications (1)

Application Number Title Priority Date Filing Date
GB2300774.3A Pending GB2612481A (en) 2020-06-09 2021-06-07 A novel medicament for immune modulation and treating chronic or hyper inflammation

Country Status (3)

Country Link
AU (1) AU2021286756A1 (en)
GB (1) GB2612481A (en)
WO (1) WO2021249608A2 (en)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741802A (en) * 1992-08-31 1998-04-21 University Of Florida Anabaseine derivatives useful in the treatment of degenerative diseases of the nervous system
WO1999010338A2 (en) * 1997-08-29 1999-03-04 University Of Florida Benzylidene- and cinnamylidene-anabaseines as neuronal nicotinic alpha-7 receptor agonists
US20050288333A1 (en) * 2004-06-08 2005-12-29 Kem William R Controlling angiogenesis with anabaseine analogs
US20070232651A1 (en) * 2006-01-26 2007-10-04 Habgood Gregory J Novel anabaseine derivatives, pharmaceutical compositions and methods of use thereof
US9387201B2 (en) * 2011-08-29 2016-07-12 Rcp Development, Inc. Methods of providing anti-inflammation support
US20180139961A1 (en) * 2016-11-20 2018-05-24 Iowa State University Research Foundation, Inc. (s)-5-ethynyl-anabasine, derivatives thereof, and related compositions and methods of making and using
WO2019202396A1 (en) * 2018-04-16 2019-10-24 Poviva Tea, Llc Compositions infused with nicotine compounds and methods of use thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741802A (en) * 1992-08-31 1998-04-21 University Of Florida Anabaseine derivatives useful in the treatment of degenerative diseases of the nervous system
WO1999010338A2 (en) * 1997-08-29 1999-03-04 University Of Florida Benzylidene- and cinnamylidene-anabaseines as neuronal nicotinic alpha-7 receptor agonists
US20050288333A1 (en) * 2004-06-08 2005-12-29 Kem William R Controlling angiogenesis with anabaseine analogs
US20070232651A1 (en) * 2006-01-26 2007-10-04 Habgood Gregory J Novel anabaseine derivatives, pharmaceutical compositions and methods of use thereof
US9387201B2 (en) * 2011-08-29 2016-07-12 Rcp Development, Inc. Methods of providing anti-inflammation support
US20180139961A1 (en) * 2016-11-20 2018-05-24 Iowa State University Research Foundation, Inc. (s)-5-ethynyl-anabasine, derivatives thereof, and related compositions and methods of making and using
WO2019202396A1 (en) * 2018-04-16 2019-10-24 Poviva Tea, Llc Compositions infused with nicotine compounds and methods of use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
E. SHULTSA et al., "Anabasine as a Precursor for the Synthesis of Potential Agonists of Neuronal Acetylcholine Receptors E.", Doklady Chemistry,2007, Vol. 413, Part 1, pp. 59-63. Abs., page 59, compound IV *
Ya. Lukomskaya et al. CHOLINERGIC EFFECTIVENESS OF ANABASINE DERIVATIVES N."I. M. Sechenov Institute of Evolutionary Physiology and Biochemistry, Academy of Sciences of the USSR, Leningrad", Institute of National Economy, Tashkent. Translated from Khimiko-farmatsevticheskii Zhumal, Vol. 24, No.7, pp *

Also Published As

Publication number Publication date
AU2021286756A1 (en) 2023-03-23
WO2021249608A2 (en) 2021-12-16
GB202300774D0 (en) 2023-03-08
WO2021249608A3 (en) 2022-02-03
WO2021249608A4 (en) 2022-04-07

Similar Documents

Publication Publication Date Title
Xu et al. Safety and complications of intravitreal injections performed in an Asian population in Singapore
RU2012148710A (en) ORGANIC COMPOUND FOR USE IN TREATMENT OF LIVER CANCER
JP5026255B2 (en) Infectious disease treatment
JP2018513188A5 (en)
Botzenhardt et al. Safety profiles of iron chelators in young patients with haemoglobinopathies
Minor et al. Prolonged methylene blue infusion in refractory septic shock: a case report
Lin Desensitization in the management of vancomycin hypersensitivity
JP2017514911A5 (en)
WO2022039619A1 (en) Antiviral agent for combined therapy of covid-19 (sars-cov-2)
Bossé et al. Severe anaphylaxis caused by orally administered vancomycin to a patient with Clostridium difficile infection
Belchí-Hernández et al. Management of adverse reactions to prophylactic trimethoprim-sulfamethoxazole in patients with human immunodeficiency virus infection
GB2612481A (en) A novel medicament for immune modulation and treating chronic or hyper inflammation
Abrams-Downey et al. Investigational therapies for the treatment of COVID-19: updates from ongoing clinical trials
Oh et al. Safety and efficacy of conversion from twice-daily tacrolimus to once-daily tacrolimus one month after transplantation: randomized controlled trial in adult renal transplantation
US11253488B2 (en) Sublingual epinephrine tablets
Brahmantya et al. COVID-19 pharmacological treatment at the Udayana University Hospital in april-may 2020
Edwards et al. Early-onset rhabdomyolysis associated with daptomycin
Cheesman Sickle cell disease: symptoms, complications and management
US20200001109A1 (en) Methods For Treating Hyperbilirubinemia With Stannsoporfin And Phototherapy
Roberts The CRASH-2 trial of an antifibrinolytic agent in traumatic haemorrhage: an international collaboration
Fattizzo et al. Monitoring of Patients with Autoimmune Cytopenias during Sars-Cov-2 Vaccination Campaign: The Experience of a Reference Center
Inocian et al. Pharmacotherapeutics and Vaccines for COVID-19
Schellong et al. Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient: an analysis of the CERTIFY study
Neki et al. Anaphylactic reaction to intravenous artesunate: a case report
高気圧酸素療法で治療した犬の難治性創傷 A non-healing wound in a dog treated with hyperbaric oxygen therapy